DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8lwbqx/metastatic) has announced the addition of the "Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Aduro BioTech, Inc.
- Amgen Inc.
- Axcentua Pharmaceuticals AB
- BioCancell Therapeutics, Inc.
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Eleison Pharmaceuticals, Inc.
- Gilead Sciences, Inc.
- Halozyme Therapeutics, Inc.
- Incyte Corporation
- Millennium Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- NewLink Genetics Corporation
- Novartis AG
- Phoenix Biotechnology, Inc.
- Sanofi
- Teva Pharmaceutical Industries Limited
- Threshold Pharmaceuticals, Inc.
Drug Profiles
- AXP-10711
- BBI-608
- BC-819
- BI-853520
- binimetinib
- CEP-37250
- CRS-207
- Dendritic Cell Therapy for Cancer
- erismodegib
- evofosfamide
- ganitumab
- glufosfamide
- indoximod
- LGK-974
- MesoCART
- MLN-0264
- paclitaxel lipsomal
- PBI-05204
- PEGPH-20
- plerixafor
- PRI-724
- ruxolitinib phosphate
- SiG12D-LODER
- simtuzumab
- Stem Cell Therapy for Oncology
- Triapine
For more information visit http://www.researchandmarkets.com/research/8lwbqx/metastatic
